Jeffrey Stoss - Molecule Holdings Chief Officer
| EVRRF Stock | USD 0 0.00 0.00% |
Insider
Jeffrey Stoss is Chief Officer of Molecule Holdings
| Phone | 613-809-1814 |
| Web | https://www.molecule.ca |
Molecule Holdings Management Efficiency
The company has return on total asset (ROA) of (0.4066) % which means that it has lost $0.4066 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (10.8843) %, meaning that it generated substantial loss on money invested by shareholders. Molecule Holdings' management efficiency ratios could be used to measure how well Molecule Holdings manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Hlio Segouras | Hypera SA | N/A | |
| Masaya Toda | Nippon Shinyaku Co | N/A | |
| Julious Grant | Canopy Growth Corp | 56 | |
| A MBA | Cumberland Pharmaceuticals | 66 | |
| L Porres | Genomma Lab Internacional | N/A | |
| Thomas Shipley | Canopy Growth Corp | 30 | |
| Engineer Galland | Genomma Lab Internacional | N/A | |
| William Newlands | Canopy Growth Corp | 62 | |
| Adalmario Couto | Hypera SA | N/A | |
| Juliana Salem | Hypera SA | N/A | |
| Jonathan Tosto | Canopy Growth Corp | N/A | |
| Toru Nakai | Nippon Shinyaku Co | 52 | |
| Theresa Yanofsky | Canopy Growth Corp | 63 | |
| Theresa Firestone | Aurora Cannabis | 65 | |
| Mximo Juda | Genomma Lab Internacional | N/A | |
| Takanori Edamitsu | Nippon Shinyaku Co | 60 | |
| Thomas Stewart | Canopy Growth Corp | 42 | |
| Jakob Feinstein | Curaleaf Holdings | N/A | |
| Kazuchika Takagaki | Nippon Shinyaku Co | 62 | |
| Takashi Takaya | Nippon Shinyaku Co | 63 | |
| Luiz Clavis | Hypera SA | N/A | |
Management Performance
| Return On Equity | -10.88 | |||
| Return On Asset | -0.41 |
Molecule Holdings Leadership Team
Elected by the shareholders, the Molecule Holdings' board of directors comprises two types of representatives: Molecule Holdings inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Molecule. The board's role is to monitor Molecule Holdings' management team and ensure that shareholders' interests are well served. Molecule Holdings' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Molecule Holdings' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeffrey Stoss, Chief Officer | ||
| Becky Griffin, Chief Officer | ||
| Tiago Zamponi, Head Sales | ||
| David Reingold, Pres CEO | ||
| Andre BComm, CoFounder Chairman | ||
| Amy Proulx, CoFounder Director | ||
| Philip Waddington, COO Director |
Molecule Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Molecule Holdings a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.88 | |||
| Return On Asset | -0.41 | |||
| Profit Margin | (2.43) % | |||
| Operating Margin | (2.15) % | |||
| Current Valuation | 5.39 M | |||
| Shares Outstanding | 97.78 M | |||
| Shares Owned By Insiders | 16.52 % | |||
| Price To Earning | (2.27) X | |||
| Price To Book | 12.35 X | |||
| Price To Sales | 0.0001 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Molecule Pink Sheet
Molecule Holdings financial ratios help investors to determine whether Molecule Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Molecule with respect to the benefits of owning Molecule Holdings security.